TCGA-A8-A08C-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 29
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.370
- ADIPOGENESIS+0.200
- MYC_TARGETS_V2+0.160
- MYC_TARGETS_V1+0.130
- PEROXISOME+0.090
- WNT_BETA_CATENIN_SIGNALING+0.090
- BILE_ACID_METABOLISM+0.070
- MITOTIC_SPINDLE+0.060
- OXIDATIVE_PHOSPHORYLATION+0.060
- DNA_REPAIR+0.040
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.460
- ALLOGRAFT_REJECTION-0.380
- ANGIOGENESIS-0.380
- E2F_TARGETS-0.370
- INTERFERON_GAMMA_RESPONSE-0.360
- KRAS_SIGNALING_UP-0.360
- TNFA_SIGNALING_VIA_NFKB-0.360
- IL6_JAK_STAT3_SIGNALING-0.350
- COMPLEMENT-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168565 | — | — | 0.931 |
| 2 | MDT-AP-3207 | Med | Medulloblastoma | 0.905 |
| 3 | TCGA-AR-A0TR-01A-11R-A084-07 | — | B | 0.902 |
| 4 | MDT-AP-0395 | Med | Medulloblastoma | 0.898 |
| 5 | SRR8943016 | — | — | 0.892 |
| 6 | TCGA-A2-A0D3-01A-11R-A115-07 | — | B | 0.887 |
| 7 | MDT-AP-1341 | Med | Medulloblastoma | 0.885 |
| 8 | MBCProject_0343_T1_RNA | — | B | 0.880 |
| 9 | BS_SDCNP7MW | EPN | EPN Tumor | 0.874 |
| 10 | SRR23303735 | — | — | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.060 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |